Characiejus Dainius, Pasukoniene Vita, Kazlauskaite Nijole, Valuckas Konstantinas P, Petraitis Tadas, Mauricas Mykolas, Den Otter Willem
Institute of Oncology, Vilnius University, Santariskiu 1, LT-2600 Vilnius, Lithuania.
Anticancer Res. 2002 Nov-Dec;22(6B):3679-83.
The aim of this retrospective study was to evaluate the significance of pre-treatment levels of peripheral blood lymphocyte subsets for survival of renal cell carcinoma (RCC) patients treated with interferon-a2b (IFN).
CD3+, CD19+, CD16&56+, CD4+, CD8+, CD4+CD45ROhigh and CD8highCD57+ lymphocyte subsets in peripheral blood of 85 advanced RCC patients were determined using flow cytometry. The survival of IFN-treated and non-treated patients was analyzed by gradually testing different cut-off levels of each lymphocyte subset.
Advanced RCC patients with > or = 30% CD8highCD57+ lymphocytes in the CD8+ subset had shorter survival compared to patients with < 30% CD8highCD57+ lymphocytes in the CD8+ subset (p = 0.01). Treatment with IFN increased overall survival only in the former subgroup of RCC patients (p = 0.02).
The present study suggests that the percentage of CD8highCD57+ lymphocytes in the CD8+ subset may have a prognostic significance for advanced RCC patients and may have a predictive value in patient selection for survival benefit due to treatment with IFN.
这项回顾性研究的目的是评估外周血淋巴细胞亚群的治疗前水平对接受干扰素 - a2b（IFN）治疗的肾细胞癌（RCC）患者生存的意义。
采用流式细胞术测定85例晚期RCC患者外周血中CD3 +、CD19 +、CD16&56 +、CD4 +、CD8 +、CD4 + CD45RO高表达和CD8高表达CD57 +淋巴细胞亚群。通过逐步检测每个淋巴细胞亚群的不同临界水平，分析接受IFN治疗和未接受治疗患者的生存率。
与CD8 +亚群中CD8高表达CD57 +淋巴细胞＜30%的患者相比，CD8 +亚群中CD8高表达CD57 +淋巴细胞≥30%的晚期RCC患者生存期较短（p = 0.01）。仅在RCC患者的前一个亚组中，IFN治疗可提高总生存率（p = 0.02）。
本研究表明，CD8 +亚群中CD8高表达CD57 +淋巴细胞的百分比可能对晚期RCC患者具有预后意义，并且在因IFN治疗而有生存获益的患者选择中可能具有预测价值。
